Folotyn for Non-Hodgkin's Lymphoma Nyack NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Norman Lester Rosen
(914) 965-2060
3333 Henry Hudson Way
Bronx, NY
AMIT VERMA, MD
(718) 405-8536
111 East 210Th Street
Bronx, NY
MICHAEL RADER, MD
(845) 348-2198
160 N Midland Avenue
Nyack, NY
MARTHA WONG, MD
(718) 901-8101
1770 Grand Concourse
Bronx, NY
Jill Suzanne Menell, MD
25 Rockwood Pl
Englewood, NJ
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
Steven Edward Vogl
(718) 519-7774
2220 Tiemann Ave
Bronx, NY
NANCY GREEN, MD
(212) 304-7250
3959 Broadway
New York, NY
ROBERT GALLAGHER, MD
(718) 920-4057
111 East 210Th Street
Bronx, NY
Marc Steven Zimmerman, MD
845-362-3970
974 Route 45 Ste 1200
Pomona, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Nyack NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Nyack NY